# A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma

> **NCT07650266** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 60 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma
- Nasopharyngeal Cancer
- Nasopharynx Carcinoma
- Nasopharynx Cancer

## Interventions

- **DRUG:** Cemiplimab
- **DRUG:** Fianlimab

## Key facts

- **NCT ID:** NCT07650266
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2030-07
- **Final completion:** 2030-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-08-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07650266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07650266, "A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07650266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*